[Tissue biomarkers in prostate cancer.] / Biomarcadores tisulares en cáncer de próstata.

INTRODUCTION: Prostate cancer is themost prevalent and deadliest neoplasm in men, with adiverse clinical presentantion and oncological outcomes.The diagnosis and treatment remains a challenge.New essays about biomarkers show their potential asa tool that may influence in clinical decision making,risk stratification and management of the disease. METHODS: we performed a literature review abouttissue biomarkers in the diagnosis and treatment ofprostate cancer. RESULTS: Within the last years, a wide number ofdiagnostic and prognostic tests in tissue have been developed(ConfirmMDx, Promark, Oncoytype DX, Decipher),creating an opportunity to improve the diagnosis,prognosis and treatment of prostate cancer. CONCLUSIONS: Since prostate cancer is the mostprevalent neoplasm in men, it is mandatory to stratifypatients correctly to prevent unnecessary biopsiesand overtreatment in low risk patients, as well as designthe best strategy in those with high risk disease.Tissue biomarkers may become a useful tool in precisionmedicine to guide decision making.

INTRODUCCIÓN: El cáncer de próstataes el cáncer no cutáneo más prevalente en los hombresy la principal causa de muerte relacionada con tumoren varones. Es una neoplasia maligna con una presentaciónclínica y resultados oncológicos muy variables.El diagnóstico y el tratamiento siguen siendo un desafíoy, en ocasiones, se vuelven muy controvertidos. Losnuevos ensayos de biomarcadores se han mostradoprometedores como una herramienta complementariapara ayudar en la toma de decisiones, en la estratificacióndel riesgo y en el manejo de la enfermedad.MÉTODOS: Revisamos la literatura actual sobre eluso de biomarcadores tisulares en las decisiones dediagnóstico y tratamiento en el cáncer de próstata.RESULTADOS: En los últimos años han surgido unaamplia gama de pruebas de diagnóstico y pronósticodel cáncer de próstata en tejido tumoral (ConfirmMDx,Promark, Oncoytype DX, Decipher). El desarrollo deestos métodos ha creado nuevas oportunidades paramejorar el diagnóstico, el pronóstico y las decisionesde tratamiento del cáncer de próstata. CONCLUSIONES: Dado que el cáncer de próstata esuno de los tumores más prevalentes en los varones yen nuestro medio, es deseable estratificar adecuadamenteel riesgo de los pacientes para evitar biopsias innecesarias y sobretratamiento en pacientes de bajoriesgo y guiar estrategias de tratamiento adecuadas enpacientes de alto riesgo. Los biomarcadores tisularespueden resultar en herramientas complementariasútiles de la medicina de precisión para ayudar en latoma de decisiones compartida y para dirigir las decisionesde tratamiento.

[Interpretation of the metabolic study in renal lithiasis and its treatment]. / Interpretación del estudio metabólico en la litiasis renal y su tratamiento.

Urolithiasis is a common disease, and is an important health problem that is associated with a great economic burden. The nature of stone disease varies according by dietary and lifestyle factors, including, among others, climate variations. The majority of patients will suffer a new lithiasic episode at some point in their life, unless preventive measures, such as changing lifestyles and dietary habits, are put in place to avoid it. The risk factors involved in lithogenesis should be evaluated in order to reduce recurrences. In the majority of these patients, metabolic changes are observed in the urine that predispose lithogenesis. The kind of evaluation depends on stone composition and on the clinical presentation. A diagnosis of systemic and renal diseases of lithogenic nature can be diagnosed with these studies, and they also enable the adoption of precise prophylactic measures that achieve control of recurrence in a great number of patients.

Análisis comparativo de la expresión de metaloproteasas (MMP-2, MMP-9, MMP-11 y MMP-13) y del inhibidor tisular de la metaloproteasa 3 (TIMP-3) entre las biopsias previas negativas y las prostatectomías radicales / Comparative analysis of the expression of metalloproteases (MMP-2, MMP-9, MMP-11 and MMP-13) and the tissue inhibitor of metalloprotease 3 (TIMP-3) between previous negative biopsies and radical prostatectomies

Las metaloproteasas (MMP) y el inhibidor tisular de metaloproteasas 3 (TIMP-3) se han relacionado con el riesgo de padecer cáncer y con la agresividad de varios tumores. En ocasiones, existen muchas dificultades para diagnosticar el cáncer de próstata y la expresión de MMP y del TIMP-3 en biopsias negativas nos podría ayudar a realizar una sospecha diagnóstica en estos casos. El objetivo es hacer un estudio comparativo de la expresión de MMP y TIMP-3 en las biopsias previas negativas y las prostatectomías radicales (PR). MATERIAL Y MÉTODOS: Análisis retrospectivo de una cohorte de base hospitalaria que incluye a 21 pacientes con sospecha de carcinoma prostático en los que se analizaron por técnica inmunohistoquímica las expresiones de MMP-2, 9, 11 y 13 y el TIMP-3 en la zona tumoral, tanto de las biopsias previas negativas como de las PR. RESULTADOS: Los valores de tinción inmunohistoquímicos (score) para las MMP (-11 y -13) y TIMP-3 no mostraron diferencias significativas al comparar las áreas de las biopsias negativas donde luego se desarrolló tumor con las de la PR. Sin embargo, sí que observamos una diferencia significativa aumentando la expresión de la MMP-2 (p = 0,002) y MMP-9 (p = 0,001) en la zona tumoral de la PR con respecto al área correspondiente de la biopsia previa negativa. CONCLUSIONES: Nuestros datos indican una mayor expresión global de la MMP-2 y la MMP-9 en la zona tumoral de la PR en comparación con las áreas correspondientes de la biopsia previa negativa, lo que parece estar en relación con el proceso de transformación maligna

Metalloproteases (MMPs) and tissue inhibitor of metalloprotease-3 (TIMP-3) have been associated to the risk of having cancer and tumor aggressiveness. When facing the difficulties of prostate cancer diagnosis, the expression of MMPs and TIMP-3 in negative biopsies could be helpful to evaluate a diagnostic suspicion. Our objective is to carry out a comparative study of the expression of MMPs and TIMP-3 in previous negative biopsies and radical prostatectomies (RP). MATERIAL AND METHODS: Retrospective analysis of a hospital-based cohort including 21 patients with suspicion of prostate carcinoma, whose expressions of MMP-2, 9, 11 and 13 and TIMP-3 were evaluated by immunohistochemistry in the tumor area from previous negative biopsies and RP. RESULTS: Immunohistochemical staining values (Score) for MMPs (-11 and -13) and TIMP-3 showed no significant differences when comparing the areas of negative biopsies where tumors subsequently developed with those of the RP. However, we did observe a significant difference in the increased expression of MMP-2 (P = .002) and MMP-9 (P = .001) in the tumor area of the RP with respect to the corresponding area of the previous negative biopsy. CONCLUSIONS: Our data indicate a higher overall expression of MMP-2 and MMP-9 in the tumor area of the RP compared to the corresponding areas of the negative previous biopsy, which seems to be associated to the process of malignant transformation

Comparative analysis of the expression of metalloproteases (MMP-2, MMP-9, MMP-11 and MMP-13) and the tissue inhibitor of metalloprotease 3 (TIMP-3) between previous negative biopsies and radical prostatectomies. / Análisis comparativo de la expresión de metaloproteasas (MMP-2, MMP-9, MMP-11 y MMP-13) y del inhibidor tisular de la metaloproteasa 3 (TIMP-3) entre las biopsias previas negativas y las prostatectomías radicales.

Metalloproteases (MMPs) and tissue inhibitor of metalloprotease-3 (TIMP-3) have been associated to the risk of having cancer and tumor aggressiveness. When facing the difficulties of prostate cancer diagnosis, the expression of MMPs and TIMP-3 in negative biopsies could be helpful to evaluate a diagnostic suspicion. Our objective is to carry out a comparative study of the expression of MMPs and TIMP-3 in previous negative biopsies and radical prostatectomies (RP). MATERIAL AND METHODS: Retrospective analysis of a hospital-based cohort including 21 patients with suspicion of prostate carcinoma, whose expressions of MMP-2, 9, 11 and 13 and TIMP-3 were evaluated by immunohistochemistry in the tumor area from previous negative biopsies and RP. RESULTS: Immunohistochemical staining values (Score) for MMPs (-11 and -13) and TIMP-3 showed no significant differences when comparing the areas of negative biopsies where tumors subsequently developed with those of the RP. However, we did observe a significant difference in the increased expression of MMP-2 (P=.002) and MMP-9 (P=.001) in the tumor area of the RP with respect to the corresponding area of the previous negative biopsy. CONCLUSIONS: Our data indicate a higher overall expression of MMP-2 and MMP-9 in the tumor area of the RP compared to the corresponding areas of the negative previous biopsy, which seems to be associated to the process of malignant transformation.

[Renal cell carcinoma with (tubule) papillary architecture. Report of three cases and bibliographic review.] / Carcinoma de células renales con arquitectura (túbulo) papilar. Presentación de tres casos y revisión de la literatura.

OBJECTIVE: Update of clear cell (tubulo) papillary renal cell carcinoma. METHODS: We provide the only three cases described to date in our hospital. RESULTS: One of the new entities of epithelial renal tumors incorporated by the International Society of Urological Pathology (ISUP) in 2013 was the clear cell (tubulo) papillary renal cell carcinoma (RCCtpcc). Although initially was described under other nomenclatures, it was not until 2013 that it was clearly defined. CONCLUSION: The RCCtpcc is usually a low grade and stage subtype of epithelial RCC. It predominates in the sixth decade of life, although cases have already been described in children and young adults. It has a typical immunohistochemical pattern with positive CK7, vimentine, VT and smooth muscle antigen, and negative CD10. They usually have a low malignant potential.

OBJETIVO: Puesta al día del CCR túbulo papilar de células claras. MÉTODO: Aportamos los únicos tres casos descritos hasta la actualidad en nuestro hospital. RESULTADO: Una de las nuevas entidades de tumores renales epiteliales incorporadas por la International Society of Urological Pathology (ISUP) en el año 2013 es el carcinoma de células renales (tubulo) papilar de células claras (CCRtp). Aunque en un principio fue descrito bajo otras nomenclaturas, no es hasta esa fecha cuando se recogen las características que lo definen. CONCLUSIONES: El CCRtp es un subtipo de CCR epitelial, por lo general de bajo grado y estadio. Predomina en la sexta década, aunque ya están descritos casos en niños y adultos jóvenes. Su patrón inmuno-histoquímico característico es: CK7 positivo; CD10 negativo, Vimentina positivo, VT positivo y Antígeno músculo liso positivo. Por lo general son de bajo potencial maligno.

Carcinoma de células renales con arquitectura (túbulo) papilar. Presentación de tres casos y revisión de la literatura / Renal cell carcinoma with (tubule) papillary architecture. Report of three cases and bibliographic review

Objetivo: Puesta al día del CCR túbulo papilar de células claras. Método: Aportamos los únicos tres casos descritos hasta la actualidad en nuestro hospital. Resultado: Una de las nuevas entidades de tumores renales epiteliales incorporadas por la International Society of Urological Pathology (ISUP) en el año 2013 es el carcinoma de células renales (tubulo) papilar de células claras (CCRtp). Aunque en un principio fue descrito bajo otras nomenclaturas, no es hasta esa fecha cuando se recogen las características que lo definen. Conclusiones: El CCRtp es un subtipo de CCR epitelial, por lo general de bajo grado y estadio. Predomina en la sexta década, aunque ya están descritos casos en niños y adultos jóvenes. Su patrón inmuno-histoquímico característico es: CK7 positivo; CD10 negativo, Vimentina positivo, VT positivo y Antígeno músculo liso positivo. Por lo general son de bajo potencial maligno

Objective: Update of clear cell (tubulo) papillary renal cell carcinoma. Methods: We provide the only three cases described to date in our hospital. Results: One of the new entities of epithelial renal tumors incorporated by the International Society of Urological Pathology (ISUP) in 2013 was the clear cell (tubulo) papillary renal cell carcinoma (RCCtpcc). Although initially was described under other nomenclatures, it was not until 2013 that it was clearly defined. Conclusion: The RCCtpcc is usually a low grade and stage subtype of epithelial RCC. It predominates in the sixth decade of life, although cases have already been described in children and young adults. It has a typical immunohistochemical pattern with positive CK7, vimentine, VT and smooth muscle antigen, and negative CD10. They usually have a low malignant potential

Amiloidosis vesical: presentación de 5 casos / Bladder amyloidosis: study of 5 cases

No disponible

Problemas de la esfera sexual en el paciente renal / Sexual disorders in the renal patient

En la actualidad se considera a la calidad de vida relacionada con la salud como uno de los objetivos terapéuticos primordiales en pacientes que precisan tratamiento sustitutivo para seguir viviendo. La salud sexual es un derecho básico que afecta positivamente a la calidad de vida. Aunque una parte significativa de pacientes crónicos presenta algún tipo de disfunción sexual, esta no se plantea abiertamente en la consulta. Es importante que el médico aborde la dimensión sexual de estos pacientes. Repasamos la fisiopatología de las disfunciones sexuales del paciente renal crónico, tanto en hombres como en mujeres. Explicamos los efectos de la diálisis y el trasplante sobre la función sexual. Y exponemos las principales disfunciones sexuales y su tratamiento

Quality of Life Related to Health is currently considered one of the primary therapeutic objectives in renal failure patients who need substitution treatment as life prolonging therapy. Sexual health is a basic right that positively affects the quality of life. Although a significant percentage of chronic patients have some type of sexual dysfunction, this is not openly discussed, making it important for doctors to address these issues in the clinic. A review is presented on the pathophysiology of sexual dysfunctions in both male and female chronic renal patients. The effects of dialysis and transplantation on sexual function will be addressed, as well as presenting the main sexual dysfunctions and their treatment

[Sexual disorders in the renal patient]. / Problemas de la esfera sexual en el paciente renal.

Quality of Life Related to Health is currently considered one of the primary therapeutic objectives in renal failure patients who need substitution treatment as life prolonging therapy. Sexual health is a basic right that positively affects the quality of life. Although a significant percentage of chronic patients have some type of sexual dysfunction, this is not openly discussed, making it important for doctors to address these issues in the clinic. A review is presented on the pathophysiology of sexual dysfunctions in both male and female chronic renal patients. The effects of dialysis and transplantation on sexual function will be addressed, as well as presenting the main sexual dysfunctions and their treatment.

Resultados de la adrenalectomía en la metástasis del cáncer de pulmón / Results of adrenalectomy in lung cancer metastases

Introducción: El objetivo de este estudio es describir la experiencia en nuestro centro sobre pacientes con carcinoma de pulmón y metástasis adrenal tratados de manera secuencial, resección pulmonar y adrenalectomía, en los últimos 15 años. Pacientes y método: Analizamos una serie retrospectiva de 19 pacientes a los que se les realizó adrenalectomía por metástasis de carcinoma de pulmón. Todos los pacientes fueron operados en un mismo centro, entre octubre de 2000 y octubre de 2015. Se llevó a cabo un análisis descriptivo y de supervivencia global y libre de enfermedad. Resultados: Se incluyeron 13 varones y 6 mujeres. El tumor primario de pulmón más frecuente fue el adenocarcinoma, siendo el 87,5% G3. En 7 pacientes la metástasis adrenal se detectó de forma sincrónica, y en 12 metacrónica. El tamaño mediano de la metástasis fue de 63mm. El 21% de los casos presentaron recidiva local y el 79% metástasis a distancia. La mediana para la SLE fue de 21.5 meses, mientras la estimación de la SLE a 5 años fue del 58,33%. La mediana para la supervivencia global fue de 37,3 meses, mientras la estimación de la supervivencia a los 5 años fue del 42,86%. Ninguno de los factores pronósticos evaluados tuvieron significación estadística. Conclusiones: La adrenalectomía en casos de metástasis aislada de carcinoma de pulmón puede ofrecer una mayor supervivencia global. La edad y el grado de diferenciación del primario pulmonar son los factores que más influirían en una peor supervivencia

Background: The aim of this study was to report our centre's experience over the past 15 years with patients with lung carcinoma and adrenal metastases treated sequentially with lung resection and adrenalectomy. Patients and methods: We analysed a retrospective series of 19 patients who underwent adrenalectomy for lung carcinoma metastasis. All patients were operated on at the same centre, between October 2000 and October 2015. We performed a descriptive analysis and an overall survival and disease-free survival analysis. Results: The study included 13 men and 6 women. The most common primary lung tumour was adenocarcinoma, 87.5% of which were G3. In 7 patients, the adrenal metastasis was detected synchronously, and in 12 patients it was detected metachronously. The median size of the metastasis was 63mm. Twenty-one percent of the cases presented local recurrence, and 79% presented distant metastasis. The median DFS was 21.5 months, while the DFS at 5 years was calculated at 58.33%. The median overall survival was 37.3 months, while survival at 5 years was calculated at 42.86%. None of the prognostic factors evaluated were statistically significant. Conclusions: Adrenalectomy in cases of isolated lung carcinoma metastasis can offer increased overall survival. Age and the degree of differentiation of the primary lung carcinoma are the factors that most influence poorer survival

Qué debe saber el médico de primaria sobre los nuevos marcadores en el cáncer de próstata / What primary care physicians should know about new markers in prostate cancer

La utilización del antígeno prostático específico como herramienta diagnóstica en el cribado del cáncer de próstata se ve reflejada en un incremento en la incidencia, un incremento en el diagnóstico de cánceres más precoces y un aumento en los tratamientos con intención curativa, aun a costa de un sobretratamiento. Sabemos, por datos recogidos en la literatura, que no todo paciente con antígeno prostático específico elevado necesita biopsia, y que no todo paciente con diagnóstico de cáncer de próstata necesita tratamiento. Con los nuevos marcadores prostáticos emergentes vamos a tratar de mejorar la especificidad del antígeno prostático específico en la zona gris (4-10 ng/ml) evitando biopsias innecesarias, de mejorar la sensibilidad en la detección de cáncer de próstata significante con antígeno prostático específico bajo y a intentar reducir el riesgo de sobretratamiento. Por otro lado, los biomarcadores pronósticos con test genómicos nos van a ayudar a elegir la mejor opción terapéutica para el paciente

The use of prostate-specific antigen as a diagnostic tool in the screening of prostate cancer is reflected in an increase in the incidence, an increase in diagnosis at initial stages, and an increase in radical therapies, even at the expense of over-treatment in some cases. It is known from the data collected in the literature that not every patient with high prostate-specific antigen needs a biopsy, and that not every patient diagnosed with prostate cancer needs treatment. With the new emerging prostate markers, we will try to improve the specificity of prostate-specific antigen in the grey area (4-10 ng/ml) should be improved. This should avoid unnecessary biopsies. The sensitivity in the detection of significant prostate cancer with low prostate-specific antigen should also be improved in an attempt to reduce the risk of over-treatment. On the other hand, prognostic biomarkers with genomic tests will help to choose the best therapeutic option for the patient

[What primary care physicians should know about new markers in prostate cancer]. / Qué debe saber el médico de primaria sobre los nuevos marcadores en el cáncer de próstata.

The use of prostate-specific antigen as a diagnostic tool in the screening of prostate cancer is reflected in an increase in the incidence, an increase in diagnosis at initial stages, and an increase in radical therapies, even at the expense of over-treatment in some cases. It is known from the data collected in the literature that not every patient with high prostate-specific antigen needs a biopsy, and that not every patient diagnosed with prostate cancer needs treatment. With the new emerging prostate markers, we will try to improve the specificity of prostate-specific antigen in the grey area (4-10 ng/ml) should be improved. This should avoid unnecessary biopsies. The sensitivity in the detection of significant prostate cancer with low prostate-specific antigen should also be improved in an attempt to reduce the risk of over-treatment. On the other hand, prognostic biomarkers with genomic tests will help to choose the best therapeutic option for the patient.

[Usefulness of cold ureteral biopsy during radical cystectomy as a predictor of recurrence risk: Review of our series.] / Utilidad de la biopsia fría ureteral durante la cistectomía radical como predictor de riesgo de recidiva: revisión de nuestra serie.

OBJECTIVES: To evaluate the association of positive margins in the intraoperative biopsy during radical cystectomy (RC) with the risk of recurrence in the uretero-ileal anastomosis or upper urinary tract (UUT), and identify potential risk factors for positive ureteral margins. METHODS: A retrospective, descriptive study was performed in patients treated with radical cystectomy due to transitional cell carcinoma (TCC), who underwent a cold biopsy of the ureteral margin at the time of cystectomy. A descriptive analysis and frequency distribution was performed. Fisher's test was used to calculate sensitivity and specificity and a survival analysis was performed. RESULTS: 230 patients were included. Prior to RC, transurethral resection of the bladder tumor and a CT scan were done. The percentage of positive margins was 4.81% for the right ureter and 4.27% for the left. Recurrence was detected in the anastomosis in 2.64% of the cases. In a 0.88% recurrence was found in the UUT (2 cases) at the level of left renal pelvis (1 case) and left kidney (1 case). In the multivariate analysis, neither recurrence in the anastomosis (p=1) or at the UUT (p=1) level during follow-up were significantly associated with the presence of positive margins. An association was found between the pathological biopsy of the right ureter and carcinoma in situ (CIS) of the bladder wall with UUT involvement. We found only association between the cold biopsy of the left ureter and tumor in left UTT. Reimplantation with positive margins was not statistically associated with neither ureteroileal anastomosis or UTT relapse. A relationship was found between the cold biopsy of both ureters and the definitive pathology. CONCLUSIONS: In our study, the presence of positive ureteral margins was not associated with an increased risk of recurrence in the anastomosis or UUT. Although it remains a topic for debate, a strategy to follow may be to adapt ureteral cold biopsies to individual risk, thus perform it in patients with bladder CIS.

Utilidad de la biopsia fría ureteral durante la cistectomía radical como predictor de riesgo de recidiva: revisión de nuestra serie / Usefulness of cold ureteral biopsy during radical cystectomy as a predictor of recurrence risk: Review of our series

OBJETIVOS: Evaluar la asociación de márgenes positivos en la biopsia intra-operatoria al tiempo de la cistectomía radical (CR) con el riesgo de recidiva en la anastomosis urétero-ileal o a nivel del tracto urinario superior (TUS), y estudiar posibles factores de riesgo preoperatorios asociados con el margen ureteral positivo. MÉTODO: Estudio descriptivo retrospectivo de pacientes tratados mediante CR debido a carcinoma de células transicionales (CCT), a los que se les realizó al tiempo de la CR una biopsia fría del margen ureteral. Se realizó un análisis descriptivo y distribuciones de frecuencias. Se empleó el test de Fisher, se calcularon los valores de sensibilidad (Se) y especificidad (Sp) de la prueba, y se realizó un análisis de supervivencia. RESULTADOS: Se incluyeron 230 pacientes que fueron sometidos a CR. Previamente a la CR se les realizó resección transuretral (RTU) de vejiga y tomografía axial computarizada (TC). El porcentaje de márgenes positivos fue de 4,8% para el uréter derecho y de 4,7% para el izquierdo. Se detectó recidiva en la anastomosis en el 2,6% de los casos. En un 0,8% se encontró recidiva en el TUS (2 casos) a nivel de pelvis renal izquierda (1 caso) y riñón izquierdo (1 caso). En el análisis multivariante, ni la recidiva en la anastomosis (p=1) ni a nivel del TUS (p=1) a lo largo del seguimiento, se asociaron de forma significativa con la presencia de márgenes positivos. De forma secundaria se estudiaron los posibles factores anatomopatológicos preoperatorios asociados con el riesgo de margen positivo, encontrando asociación entre la anatomía patológica (A-P) intraoperatoria del uréter derecho y CIS en la RTU vesical y con tumor del TUS asociado. La reimplantación con margen positivo no se asoció estadísticamente con recidiva en la anastomosis ni con recidiva en el TUS. Hubo relación entre A-P intraoperatoria de ambos uréteres y la definitiva. CONCLUSIONES: En nuestro estudio, la presencia de márgenes ureterales positivos no se asociaron con mayor riesgo de recidiva en la anastomosis o en el TUS. Aunque sigue siendo un tema a debate, una estrategia a seguir puede ser adaptar la biopsia fría ureteral al riesgo individual y realizarla a pacientes con CIS vesical

OBJECTIVES: To evaluate the association of positive margins in the intraoperative biopsy during radical cystectomy (RC) with the risk of recurrence in the uretero-ileal anastomosis or upper urinary tract (UUT), and identify potential risk factors for positive ureteral margins. METHODS: A retrospective, descriptive study was performed in patients treated with radical cystectomy due to transitional cell carcinoma (TCC), who underwent a cold biopsy of the ureteral margin at the time of cystectomy. A descriptive analysis and frequency distribution was performed. Fisher's test was used to calculate sensitivity and specificity and a survival analysis was performed. RESULTS: 230 patients were included. Prior to RC, transurethral resection of the bladder tumor and a CT scan were done. The percentage of positive margins was 4.81% for the right ureter and 4.27% for the left. Recurrence was detected in the anastomosis in 2.64% of the cases. In a 0.88% recurrence was found in the UUT (2 cases) at the level of left renal pelvis (1 case) and left kidney (1 case). In the multivariate analysis, neither recurrence in the anastomosis (p=1) or at the UUT (p=1) level during follow-up were significantly associated with the presence of positive margins. An association was found between the pathological biopsy of the right ureter and carcinoma in situ (CIS) of the bladder wall with UUT involvement. We found only association between the cold biopsy of the left ureter and tumor in left UTT. Reimplantation with positive margins was not statistically associated with neither ureteroileal anastomosis or UTT relapse. A relationship was found between the cold biopsy of both ureters and the definitive pathology. CONCLUSIONS: In our study, the presence of positive ureteral margins was not associated with an increased risk of recurrence in the anastomosis or UUT. Although it remains a topic for debate, a strategy to follow may be to adapt ureteral cold biopsies to individual risk, thus perform it in patients with bladder CIS

Results of adrenalectomy in lung cancer metastases. / Resultados de la adrenalectomía en la metástasis del cáncer de pulmón.

BACKGROUND: The aim of this study was to report our centre's experience over the past 15 years with patients with lung carcinoma and adrenal metastases treated sequentially with lung resection and adrenalectomy. PATIENTS AND METHODS: We analysed a retrospective series of 19 patients who underwent adrenalectomy for lung carcinoma metastasis. All patients were operated on at the same centre, between October 2000 and October 2015. We performed a descriptive analysis and an overall survival and disease-free survival analysis. RESULTS: The study included 13 men and 6 women. The most common primary lung tumour was adenocarcinoma, 87.5% of which were G3. In 7 patients, the adrenal metastasis was detected synchronously, and in 12 patients it was detected metachronously. The median size of the metastasis was 63mm. Twenty-one percent of the cases presented local recurrence, and 79% presented distant metastasis. The median DFS was 21.5 months, while the DFS at 5 years was calculated at 58.33%. The median overall survival was 37.3 months, while survival at 5 years was calculated at 42.86%. None of the prognostic factors evaluated were statistically significant. CONCLUSIONS: Adrenalectomy in cases of isolated lung carcinoma metastasis can offer increased overall survival. Age and the degree of differentiation of the primary lung carcinoma are the factors that most influence poorer survival.

Actualización en incontinencia urinaria femenina / Female urinary incontinence: an update

La incontinencia urinaria es un síntoma muy prevalente en la población adulta femenina. Genera importantes connotaciones psicosociales y económicas, repercutiendo en la calidad de vida de las pacientes que la padecen. Es un problema infradiagnosticado, ya que las pacientes no siempre consultan por ello, por lo que es importante tenerlo presente y hacer un cribado oportunista desde atención primaria. Es difícil conocer el gasto sanitario que genera, parece que puede llegar a ser hasta el 2% del presupuesto sanitario. Todo esto hace que sea de gran importancia saber diagnosticar esta enfermedad, conocer los diferentes tipos de incontinencia que existen, sus posibles causas y los tratamientos disponibles. Para ello se presenta esta revisión, con el fin de conocer las herramientas diagnósticas y terapéuticas de las que se dispone, ver cuál es el papel de atención primaria en esta enfermedad y cuándo se debe derivar al nivel asistencial correspondiente (AU)

The urinary incontinence is a highly prevalent symptom in the adult female population. It has important psychosocial and economic connotations, and affects the quality of life of these patients. As it is an under-diagnosed problem due to patients not always consulting for it, it is very important to keep this in mind and to provide an opportunistic screening from Primary Health Care. It is difficult to determine the costs of this, but it is estimated to be the 2% of the health budget. Because of all of this, it is very important to know how to make a correct diagnose of this condition, to determine the different types of incontinence, possible causes, and treatments available. The purpose of this review is to show the different diagnostic and therapeutic tools available, to show the Primary Health Care role in this condition, and when to refer to specialist care (AU)

Aspectos actuales sobre el cribado en el cáncer de próstata / Current aspects of prostate cancer screening

Los programas de cribado de cáncer de próstata basados en la determinación sérica del antígeno específico de próstata han llevado a un sobrediagnóstico y, como consecuencia, a un sobretratamiento. Un porcentaje de varones diagnosticados de cáncer de próstata tienen un tumor que no progresará o lo hará lentamente (sobrediagnóstico o pseudoenfermedad). Esta tasa de sobrediagnóstico oscila entre el 17-50%. El cribado poblacional se define como la exploración sistemática de hombres asintomáticos. La detección precoz o cribado oportunista conlleva la búsqueda de casos individuales, siendo iniciada por el médico o el propio paciente. Ante un paciente que acuda a consulta solicitando un antígeno específico de próstata se le deben explicar una serie de cuestiones relativas al sobrediagnóstico, el sobretratamiento y los posibles daños derivados de la biopsia. Con los datos de los estudios aleatorizados sobre el antígeno específico de próstata y el cribado de cáncer de próstata, ninguna sociedad urológica recomienda realizar cribado poblacional (AU)

Screening programs for prostate cancer based on the determination of serum prostate specific antigen has led to overdiagnosis, and consequently overtreatment. A percentage of men diagnosed with prostate cancer have a tumour that will not progress, or do so slowly (overdiagnosis or pseudo-disease). This overdiagnosis rate ranges from 17-50%. Mass screening is defined as the systematic examination of asymptomatic men. Early detection or opportunistic screening involves the pursuit of individual cases being initiated by the doctor or the patient. In the case of a patient who requests a prostate specific antigen from their general practitioner, a number of issues on overdiagnosis, over-treatment and possible damage from the biopsy, should be explained to him. With data from randomised studies on prostate specific antigen and prostate cancer screening, population screening is not recommended by any urological society (AU)

[Female urinary incontinence: An update]. / Actualización en incontinencia urinaria femenina.

The urinary incontinence is a highly prevalent symptom in the adult female population. It has important psychosocial and economic connotations, and affects the quality of life of these patients. As it is an under-diagnosed problem due to patients not always consulting for it, it is very important to keep this in mind and to provide an opportunistic screening from Primary Health Care. It is difficult to determine the costs of this, but it is estimated to be the 2% of the health budget. Because of all of this, it is very important to know how to make a correct diagnose of this condition, to determine the different types of incontinence, possible causes, and treatments available. The purpose of this review is to show the different diagnostic and therapeutic tools available, to show the Primary Health Care role in this condition, and when to refer to specialist care.

[Current aspects of prostate cancer screening]. / Aspectos actuales sobre el cribado en el cáncer de próstata.

Screening programs for prostate cancer based on the determination of serum prostate specific antigen has led to overdiagnosis, and consequently overtreatment. A percentage of men diagnosed with prostate cancer have a tumour that will not progress, or do so slowly (overdiagnosis or pseudo-disease). This overdiagnosis rate ranges from 17-50%. Mass screening is defined as the systematic examination of asymptomatic men. Early detection or opportunistic screening involves the pursuit of individual cases being initiated by the doctor or the patient. In the case of a patient who requests a prostate specific antigen from their general practitioner, a number of issues on overdiagnosis, over-treatment and possible damage from the biopsy, should be explained to him. With data from randomised studies on prostate specific antigen and prostate cancer screening, population screening is not recommended by any urological society.